Abstract
Previous studies with gonadotrophin releasing hormone (GnRH/LHRH) vaccines have shown the usefulness of immunization against this hormone in prostate cancer. To this end, we have generated a completely synthetic peptide modified at position 6 and attached to the 830-844 tetanic toxoid (TT) helper T cell sequence. Through this work we have demonstrated that the GnRHm1-TT molecule was highly immunogenic when it is formulated as an oil-based emulsion adjuvated with Montanide ISA 51. That results correlated directly with testosterone reduction and tumor growth inhibition of the Dunning R3327-H androgen responsive prostate tumor model in rats. GnRHm1-TT, proved to be safe and useful for future clinical trials.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adjuvants, Immunologic / administration & dosage
-
Animals
-
Antibodies / blood
-
Cancer Vaccines / administration & dosage
-
Cancer Vaccines / immunology*
-
Cell Line, Tumor
-
Disease Models, Animal
-
Gonadotropin-Releasing Hormone / administration & dosage
-
Gonadotropin-Releasing Hormone / immunology*
-
Humans
-
Immunotherapy*
-
Male
-
Mannitol / administration & dosage
-
Mannitol / analogs & derivatives
-
Mannitol / immunology
-
Oleic Acids / administration & dosage
-
Oleic Acids / immunology
-
Peptide Fragments / administration & dosage
-
Peptide Fragments / chemical synthesis
-
Peptide Fragments / immunology
-
Prostatic Neoplasms / immunology
-
Prostatic Neoplasms / mortality
-
Prostatic Neoplasms / prevention & control
-
Prostatic Neoplasms / therapy*
-
Rats
-
Testosterone / blood
-
Tetanus Toxoid / administration & dosage
-
Tetanus Toxoid / immunology*
-
Vaccines, Synthetic / administration & dosage
-
Vaccines, Synthetic / immunology
Substances
-
Adjuvants, Immunologic
-
Antibodies
-
Cancer Vaccines
-
Oleic Acids
-
Peptide Fragments
-
Tetanus Toxoid
-
Vaccines, Synthetic
-
montanide ISA 51
-
Gonadotropin-Releasing Hormone
-
Mannitol
-
Testosterone